Literature DB >> 2709744

Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage.

J Evers1, R Bonn, A Boertz, W Cawello, H A Dickmans, M Weiss.   

Abstract

The pharmacokinetics of isosorbide dinitrate (ISDN) and its two active metabolites isosorbide-2-nitrate (IS-2-N) and isosorbide-5-nitrate (IS-5-N) were studied in 20 patients with normal and impaired renal function after repeated oral doses of standard 20 mg tablets ISDN t.i.d. Blood samples were taken in the steady-state on days 2 and 14, and the plasma concentrations were measured by electron capture capillary gas chromatography. We found a wide variation of pharmacokinetic parameters (AUCss0-8 and t1/2) of ISDN, IS-2-N, and IS-5-N in our patients. No correlation was detected between AUCss0-8 or t1/2 and the degree of renal insufficiency. No drug accumulation was observed after 14 days of administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2709744     DOI: 10.1007/BF01741389

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  9 in total

1.  Biotransformation of isosorbide dinitrate in humans.

Authors:  W H Down; L F Chasseaud; R K Grundy
Journal:  J Pharm Sci       Date:  1974-07       Impact factor: 3.534

2.  Isosorbide dinitrate bioavailability, kinetics, and metabolism.

Authors:  P Straehl; R L Galeazzi
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

3.  Pharmacokinetics of isosorbide-5-nitrate in renal failure.

Authors:  J Evers; B Krakamp; W Klimkait; H A Dickmans; J Maddock; V Luckow; W Cawello; M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].

Authors:  N Rietbrock; J Knoll; P G Merz; G Menke
Journal:  Dtsch Med Wochenschr       Date:  1985-11-22       Impact factor: 0.628

5.  Fate of isosorbide dinitrate and mononitrates in patients with renal failure.

Authors:  M G Bogaert; M T Rosseel; J Boelaert; R Daneels
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations.

Authors:  L F Chasseaud; A Darragh; E Doyle; R F Lambe; T Taylor
Journal:  J Pharm Sci       Date:  1984-05       Impact factor: 3.534

7.  Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.

Authors:  U Abshagen; G Betzien; R Endele; B Kaufmann; G Neugebauer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Isosorbide dinitrate in plasma and dialysate during haemodialysis.

Authors:  H Bauer; H Laufen; H E Franz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  [The effect of isosorbide nitrate, isosorbide-2- and 5-mononitrate on the exertion ECG and on the hemodynamics during atrial stimulation in patients with angina pectoris].

Authors:  M Stauch; N Grewe
Journal:  Z Kardiol       Date:  1979-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.